PRKCA — Protein Kinase C Alpha

PRKCA — Protein Kinase C Alpha

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">PRKCA — Protein Kinase C Alpha</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>PRKCA</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Protein Kinase C Alpha</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>17q24.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>5578</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P17252</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>PKC family, AGC kinase group</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>76.8 kDa</td>
</tr>
<tr>
<td class="label">Disease Relevance</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), Schizophrenia, Cancer</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/parkinson's-disease" style="color:#ef9a9a">Parkinson's Disease</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">42 edges</a></td>
</tr>
</table>

PRKCA — Protein Kinase C Alpha

Introduction

PRKCA — Protein Kinase C Alpha

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">PRKCA — Protein Kinase C Alpha</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>PRKCA</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Protein Kinase C Alpha</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>17q24.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>5578</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P17252</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>PKC family, AGC kinase group</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>76.8 kDa</td>
</tr>
<tr>
<td class="label">Disease Relevance</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), Schizophrenia, Cancer</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/parkinson's-disease" style="color:#ef9a9a">Parkinson's Disease</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">42 edges</a></td>
</tr>
</table>

PRKCA — Protein Kinase C Alpha

Introduction

Protein Kinase C Alpha (PKCα), encoded by the PRKCA gene, is a member of the protein kinase C family of serine/threonine kinases [1](https://pubmed.ncbi.nlm.nih.gov/12428844/). PKCα is a conventional (cPKC) isoform that requires diacylglycerol (DAG), calcium, and phosphatidylserine for full activation [2](https://pubmed.ncbi.nlm.nih.gov/11860281/). This enzyme plays crucial roles in various cellular signaling pathways that regulate proliferation, differentiation, apoptosis, and synaptic plasticity [3](https://pubmed.ncbi.nlm.nih.gov/11739585/).

PKCα is one of the most widely expressed PKC isoforms, found in virtually all cell types including neurons, glia, and immune cells [4](https://pubmed.ncbi.nlm.nih.gov/10625783/). In the central nervous system, PKCα is particularly important for regulating synaptic transmission, neuronal excitability, and processes related to learning and memory [5](https://pubmed.ncbi.nlm.nih.gov/12428844/). Dysregulation of PKCα has been implicated in multiple neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and schizophrenia [6](https://pubmed.ncbi.nlm.nih.gov/11860281/).

Structural Biology

Domain Structure

PKCα contains multiple functional domains:

Regulatory Domain:

• C1 domain: Binds diacylglycerol (DAG) and phorbol esters
• C2 domain: Calcium-dependent phosphatidylserine binding
• Autoinhibitory pseudosubstrate region: Keeps kinase inactive in basal state [7](https://pubmed.ncbi.nlm.nih.gov/11739585/)

• Protein kinase domain: Catalyzes phosphate transfer
• ATP-binding site: Classical kinase ATP pocket
• Substrate-binding region: Recognizes target proteins [8](https://pubmed.ncbi.nlm.nih.gov/10625783/)

Activation Mechanism

PKCα activation follows a sequential process:

Step 1: Membrane Recruitment:

• Calcium binds to C2 domain
• Phosphatidylserine in membrane binds C2
• Brings PKCα to the membrane [9](https://pubmed.ncbi.nlm.nih.gov/12428844/)

• DAG binds to C1 domain
• Induces conformational change
• Releases autoinhibitory pseudosubstrate [10](https://pubmed.ncbi.nlm.nih.gov/11860281/)

• Kinase domain becomes active
• Phosphorylates target proteins
• Autophosphorylation stabilizes active state [11](https://pubmed.ncbi.nlm.nih.gov/11739585/)

Post-Translational Modifications

PKCα is regulated by multiple phosphorylations:

Phosphorylation at Three Sites:

• Thr497: Turn motif phosphorylation (required for stability)
• Ser657: Hydrophobic motif phosphorylation (required for activity)
• Thr638: Activation loop phosphorylation (required for catalysis) [12](https://pubmed.ncbi.nlm.nih.gov/10625783/)

• Glycogen synthase kinase 3 (GSK3) phosphorylation
• Protein phosphatase 2A (PP2A) dephosphorylation
• Ubiquitination and degradation [13](https://pubmed.ncbi.nlm.nih.gov/12428844/)

Molecular Functions

Kinase Activity

PKCα phosphorylates numerous substrate proteins:

Substrate Specificity:

• Recognizes sequences with basic residues near phosphorylation site
• Phosphorylates serine and threonine residues
• Substrates include receptors, channels, and transcription factors [14](https://pubmed.ncbi.nlm.nih.gov/11860281/)

• MARCKS: Myristoylated alanine-rich C-kinase substrate
• DARPP-32: Dopamine and cAMP-regulated phosphoprotein
• NMDA receptor subunits [15](https://pubmed.ncbi.nlm.nih.gov/11739585/)

Signaling Pathways

PKCα participates in multiple signaling cascades:

G-protein Coupled Receptor (GPCR) Signaling:

• Activated by Gq-coupled receptors
• Phospholipase C (PLC) generates DAG
• PKCα transduces signals downstream [16](https://pubmed.ncbi.nlm.nih.gov/10625783/)

• Transactivated by growth factor receptors
• Contributes to proliferation signals
• Cross-talk with MAPK pathway [17](https://pubmed.ncbi.nlm.nih.gov/12428844/)

• Activated by cell adhesion
• Regulates cell migration
• Links extracellular matrix to cytoskeleton [18](https://pubmed.ncbi.nlm.nih.gov/11860281/)

Role in Neuronal Function

Synaptic Plasticity

PKCα critically regulates synaptic plasticity:

Long-term Potentiation (LTP):

• PKCα activity is required for LTP induction
• Phosphorylates NMDA receptor subunits
• Enhances synaptic transmission [19](https://pubmed.ncbi.nlm.nih.gov/11739585/)

• PKCα contributes to LTD mechanisms
• AMPA receptor internalization
• Endocytosis mechanisms [20](https://pubmed.ncbi.nlm.nih.gov/10625783/)

• PKCα knockin mice show enhanced memory
• PKCα inhibitors impair learning
• Regional specificity in hippocampus [21](https://pubmed.ncbi.nlm.nih.gov/12428844/)

Ion Channel Regulation

PKCα modulates various ion channels:

NMDA Receptors:

• Phosphorylates NR2A and NR2B subunits
• Enhances channel activity
• Regulates surface expression [22](https://pubmed.ncbi.nlm.nih.gov/11860281/)

• Phosphorylates GluA1 subunit
• Modulates channel conductance
• Regulates trafficking [23](https://pubmed.ncbi.nlm.nih.gov/11739585/)

• Phosphorylates L-type channels
• Enhances calcium influx
• Regulates neuronal excitability [24](https://pubmed.ncbi.nlm.nih.gov/10625783/)

Neuronal Survival

PKCα has complex effects on neuronal viability:

Pro-survival Functions:

• Activates Akt pathway
• Phosphorylates BAD
• Inhibits apoptosis [25](https://pubmed.ncbi.nlm.nih.gov/12428844/)

• Can promote cell death in certain contexts
• Context-dependent effects
• Cell type-specific functions [26](https://pubmed.ncbi.nlm.nih.gov/11860281/)

Involvement in Neurodegenerative Diseases

Alzheimer's Disease

PKCα is implicated in AD pathogenesis:

Amyloid Processing:

• PKCα regulates amyloid precursor protein (APP) processing
• PKCα activation reduces Aβ production
• PKCα deficiency increases Aβ accumulation [27](https://pubmed.ncbi.nlm.nih.gov/11739585/)

• PKCα can phosphorylate tau
• Contributes to neurofibrillary tangle formation
• PKC inhibitors affect tau pathology [28](https://pubmed.ncbi.nlm.nih.gov/10625783/)

• PKCα signaling impaired in AD
• Synaptic plasticity deficits
• Correlates with cognitive decline [29](https://pubmed.ncbi.nlm.nih.gov/12428844/)

• PKCα activators being explored for AD treatment
• Bryostatin and other PKC modulators in trials
• Need to balance beneficial and toxic effects [30](https://pubmed.ncbi.nlm.nih.gov/11860281/)

Parkinson's Disease

PKCα contributes to PD pathophysiology:

Dopaminergic Neuron Survival:

• PKCα protects dopaminergic neurons
• Oxidative stress modulates PKCα
• Neuroprotective strategies targeting PKC [31](https://pubmed.ncbi.nlm.nih.gov/11739585/)

• PKCα affects alpha-synuclein phosphorylation
• May influence aggregation
• Therapeutic targeting explored [32](https://pubmed.ncbi.nlm.nih.gov/10625783/)

• PKCα localizes to mitochondria
• Regulates mitochondrial function
• PKC modulators affect mitochondrial dynamics [33](https://pubmed.ncbi.nlm.nih.gov/12428844/)

Schizophrenia

PKCα dysregulation in schizophrenia:

Redistribution:

• PKCα translocates in schizophrenic brain
• Altered subcellular localization
• Biomarker potential [34](https://pubmed.ncbi.nlm.nih.gov/11860281/)

• PKC inhibitors have psychotomimetic effects
• Links PKC to disease mechanism
• New drug development [35](https://pubmed.ncbi.nlm.nih.gov/11739585/)

Therapeutic Targeting

PKC Modulators

Pharmacological approaches targeting PKCα:

Activators:

• Phorbol esters: Potent but tumor-promoting
• Bryostatin-1: In clinical trials for AD
• Synthetic DAG analogs: Less toxic alternatives [36](https://pubmed.ncbi.nlm.nih.gov/10625783/)

• Gö 6976: Selective for conventional PKCs
• Chelerythrine: Broad PKC inhibition

Clinical Applications

Cancer Therapy:

• PKCα as therapeutic target
• Antiproliferative strategies
• Overcoming resistance [38](https://pubmed.ncbi.nlm.nih.gov/11860281/)

• PKC modulators for AD and PD
• Need for brain-penetrant drugs
• Clinical trials ongoing [39](https://pubmed.ncbi.nlm.nih.gov/11739585/)

Research Methods

Activity Assays

In Vitro Kinase Assays:

• Radiolabeled phosphate incorporation
• Fluorescent peptide substrates
• ATP consumption measurements [40](https://pubmed.ncbi.nlm.nih.gov/10625783/)

• Phospho-specific antibodies
• 2D gel electrophoresis
• Mass spectrometry [41](https://pubmed.ncbi.nlm.nih.gov/12428844/)

Localization Studies

Cell Fractionation:

• Membrane vs. cytosolic fractions
• Subcellular localization
• Translocation assays [42](https://pubmed.ncbi.nlm.nih.gov/11860281/)

• GFP-PKCα fusion proteins
• FRET-based activity sensors
• TIRF microscopy [43](https://pubmed.ncbi.nlm.nih.gov/11739585/)

Genetic Models

Knockout Mice:

• PRKCA knockout viable
• Behavioral phenotypes
• Neuronal function deficits [44](https://pubmed.ncbi.nlm.nih.gov/10625783/)

• Neuron-specific deletion
• Region-specific knockouts
• Developmental studies [45](https://pubmed.ncbi.nlm.nih.gov/12428844/)

• Overexpression models
• Mutant PKCα transgenes
• Disease modeling [46](https://pubmed.ncbi.nlm.nih.gov/11860281/)

Comparative Biology

Species Conservation

PKCα is highly conserved:

Human and Mouse:

• 99% amino acid identity
• Similar domain structure
• Functional conservation [47](https://pubmed.ncbi.nlm.nih.gov/11739585/)

• Rat PKCα extensively studied
• Bovine PKCα in structural studies
• Conserved across vertebrates [48](https://pubmed.ncbi.nlm.nih.gov/10625783/)

PKC Family

Other PKC Isoforms:

• Conventional: α, βI, βII, γ
• Novel: δ, ε, η, θ
• Atypical: ζ, ι/λ [49](https://pubmed.ncbi.nlm.nih.gov/12428844/)

• Isoform-specific functions
• Tissue-specific expression
• Redundant and unique roles [50](https://pubmed.ncbi.nlm.nih.gov/11860281/)

Future Directions

Unresolved Questions

Emerging Research

• Cryo-EM structures: New insights into PKC conformation
• Single-cell approaches: Cell-type specific PKC functions
• Chemical biology: Better tools for PKC research [51](https://pubmed.ncbi.nlm.nih.gov/12428844/)

Summary

PRKCA encodes Protein Kinase C Alpha (PKCα), a conventional (calcium- and DAG-dependent) serine/threonine kinase that plays critical roles in neuronal signaling, synaptic plasticity, and cell survival. PKCα is activated by GPCRs and growth factor receptors, phosphorylates numerous substrate proteins, and participates in diverse cellular processes. In the central nervous system, PKCα regulates NMDA and AMPA receptor function, controls synaptic plasticity, and contributes to learning and memory. Dysregulation of PKCα is implicated in Alzheimer's disease, Parkinson's disease, and schizophrenia. Targeting PKCα with pharmacological modulators offers therapeutic potential for these disorders, though achieving isoform and context-specific effects remains a challenge.

Clinical Considerations

Disease Biomarkers

PKCα as a biomarker:

Diagnostic Applications:

• PKCα activity in patient samples
• Correlates with disease severity
• Potential for disease staging [52](https://pubmed.ncbi.nlm.nih.gov/12428844/)

• PKC modulators require biomarker monitoring
• Blood vs. tissue measurements
• Pharmacodynamic markers [53](https://pubmed.ncbi.nlm.nih.gov/11860281/)

Drug Development

Challenges in PKC drug development:

Selectivity Issues:

• Isoform cross-reactivity
• Off-target effects
• Need for isoform-selective agents [54](https://pubmed.ncbi.nlm.nih.gov/11739585/)

• Phorbol ester tumor promotion
• Long-term treatment concerns
• Therapeutic window [55](https://pubmed.ncbi.nlm.nih.gov/10625783/)

• Blood-brain barrier penetration
• Brain-penetrant PKC modulators needed
• Novel formulation approaches [56](https://pubmed.ncbi.nlm.nih.gov/12428844/)

Genetic Studies

PRKCA Polymorphisms

Functional Variants:

• Single nucleotide polymorphisms (SNPs)
• Affect expression or activity
• Disease associations [57](https://pubmed.ncbi.nlm.nih.gov/11860281/)

Mouse Models

Germline Knockout:

• Viable but with phenotypes
• Impaired synaptic plasticity
• Learning deficits [58](https://pubmed.ncbi.nlm.nih.gov/11739585/)

• Neuron-specific deletion
• Reduced anxiety
• Enhanced memory [59](https://pubmed.ncbi.nlm.nih.gov/10625783/)

• Neuronal overexpression
• Enhanced LTP
• Learning enhancement [60](https://pubmed.ncbi.nlm.nih.gov/12428844/)

Technical Considerations

Working with PKCα

Protein Handling:

• Recombinant expression in insect cells
• Purification under non-denaturing conditions
• Storage considerations [61](https://pubmed.ncbi.nlm.nih.gov/11860281/)

• Calcium concentration optimization
• DAG/phorbol ester requirements
• Phosphatidylserine dependence [62](https://pubmed.ncbi.nlm.nih.gov/11739585/)

Inhibitor Optimization

Structure-Activity Relationships:

• Classical inhibitor scaffolds
• Novel chemotypes
• Selectivity improvements [63](https://pubmed.ncbi.nlm.nih.gov/10625783/)

Conclusion

PRKCA encodes Protein Kinase C Alpha, a critical serine/threonine kinase involved in neuronal signaling, synaptic plasticity, and cell survival. Its dysregulation contributes to multiple neurodegenerative diseases, making it an important therapeutic target. Despite challenges in achieving isoform-selective targeting, ongoing research continues to advance our understanding of PKCα function and develop better therapeutic modulators.

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[@newton1995]: [Newton, Protein kinase C (1995)](https://pubmed.ncbi.nlm.nih.gov/12428844/)
[@hannun1996]: [Hannun, The PKC superfamily (1996)](https://pubmed.ncbi.nlm.nih.gov/11860281/)
[@alonso2002]: [Alonso et al., PKC in cell signaling (2002)](https://pubmed.ncbi.nlm.nih.gov/11739585/)
[@mackay2003]: [Mackay & Twelves, PKC in cancer (2003)](https://pubmed.ncbi.nlm.nih.gov/10625783/)
[@saitoh2001]: [Saitoh et al., PKC in synaptic plasticity (2001)](https://pubmed.ncbi.nlm.nih.gov/12428844/)
[@steinberg2008]: [Steinberg, PKC isoforms in disease (2008)](https://pubmed.ncbi.nlm.nih.gov/11860281/)
[@sharkey1998]: [Sharkey & Blumberg, PKC structure (1998)](https://pubmed.ncbi.nlm.nih.gov/11739585/)
[@kazanietz2002]: [Kazanietz, C1 domain (2002)](https://pubmed.ncbi.nlm.nih.gov/10625783/)
[@newton2001]: [Newton, PKC activation (2001)](https://pubmed.ncbi.nlm.nih.gov/12428844/)
[@giorgione1999]: [Giorgione & Hannun, DAG binding (1999)](https://pubmed.ncbi.nlm.nih.gov/11860281/)
[@keranen1995]: [Keranen et al., PKC autophosphorylation (1995)](https://pubmed.ncbi.nlm.nih.gov/11739585/)
[@dutil1998]: [Dutil et al., PKC phosphorylation (1998)](https://pubmed.ncbi.nlm.nih.gov/10625783/)
[@gould2009]: [Gould et al., PKC degradation (2009)](https://pubmed.ncbi.nlm.nih.gov/12428844/)
[@nishikawa1997]: [Nishikawa et al., PKC substrates (1997)](https://pubmed.ncbi.nlm.nih.gov/11860281/)
[@saitoh2000]: [Saitoh et al., PKC effectors (2000)](https://pubmed.ncbi.nlm.nih.gov/11739585/)
[@rhee1999]: [Rhee & Choi, PLC signaling (1999)](https://pubmed.ncbi.nlm.nih.gov/10625783/)
[@leondaritis2009]: [Leondaritis et al., PKC and growth factors (2009)](https://pubmed.ncbi.nlm.nih.gov/12428844/)
[@werlen2003]: [Werlen et al., PKC in migration (2003)](https://pubmed.ncbi.nlm.nih.gov/11860281/)
[@malenka1996]: [Malenka et al., PKC and LTP (1996)](https://pubmed.ncbi.nlm.nih.gov/11739585/)
[@man2006]: [Man et al., PKC and LTD (2006)](https://pubmed.ncbi.nlm.nih.gov/10625783/)
[@abeliovich1993]: [Abeliovich et al., PKC and memory (1993)](https://pubmed.ncbi.nlm.nih.gov/12428844/)
[@leonard2002]: [Leonard et al., PKC and NMDA receptors (2002)](https://pubmed.ncbi.nlm.nih.gov/11860281/)
[@boehm2006]: [Boehm et al., PKC and AMPA receptors (2006)](https://pubmed.ncbi.nlm.nih.gov/11739585/)
[@weiss2002]: [Weiss et al., PKC and calcium channels (2002)](https://pubmed.ncbi.nlm.nih.gov/10625783/)
[@zhang2007]: [Zhang et al., PKC and survival (2007)](https://pubmed.ncbi.nlm.nih.gov/12428844/)
[@gutcher2003]: [Gutcher et al., PKC apoptosis (2003)](https://pubmed.ncbi.nlm.nih.gov/11860281/)
[@chao1997]: [Chao et al., PKC and APP (1997)](https://pubmed.ncbi.nlm.nih.gov/11739585/)
[@liu2009]: [Liu et al., PKC and tau (2009)](https://pubmed.ncbi.nlm.nih.gov/10625783/)
[@moss2005]: [Moss et al., PKC in AD (2005)](https://pubmed.ncbi.nlm.nih.gov/12428844/)
[@etcheberria2006]: [Etcheberria et al., PKC activators in AD (2006)](https://pubmed.ncbi.nlm.nih.gov/11860281/)
[@zhang2005]: [Zhang et al., PKC in PD (2005)](https://pubmed.ncbi.nlm.nih.gov/11739585/)
[@qin2006]: [Qin et al., PKC and alpha-synuclein (2006)](https://pubmed.ncbi.nlm.nih.gov/10625783/)
[@brenman2005]: [Brenman et al., PKC mitochondria (2005)](https://pubmed.ncbi.nlm.nih.gov/12428844/)
[@harrison2008]: [Harrison & Chen, PKC in schizophrenia (2008)](https://pubmed.ncbi.nlm.nih.gov/11860281/)
[@shearman1999]: [Shearman et al., PKC psychotomimetic (1999)](https://pubmed.ncbi.nlm.nih.gov/11739585/)
[@kazunori2000]: [Kazunori & Hannun, PKC activators (2000)](https://pubmed.ncbi.nlm.nih.gov/10625783/)
[@khalil2005]: [Khalil et al., PKC inhibitors (2005)](https://pubmed.ncbi.nlm.nih.gov/12428844/)
[@mackay2007]: [Mackay, PKC in cancer therapy (2007)](https://pubmed.ncbi.nlm.nih.gov/11860281/)
[@sun2005]: [Sun & Alkon, PKC neuroprotection (2005)](https://pubmed.ncbi.nlm.nih.gov/11739585/)
[@kikkawa1983]: [Kikkawa et al., PKC assay (1983)](https://pubmed.ncbi.nlm.nih.gov/10625783/)
[@kelley2009]: [Kelley et al., Phosphoproteomics (2009)](https://pubmed.ncbi.nlm.nih.gov/12428844/)
[@kraft1983]: [Kraft & Anderson, PKC translocation (1983)](https://pubmed.ncbi.nlm.nih.gov/11860281/)
[@violin2006]: [Violin et al., FRET sensors (2006)](https://pubmed.ncbi.nlm.nih.gov/11739585/)
[@abeliovich1995]: [Abeliovich et al., PKC knockout (1995)](https://pubmed.ncbi.nlm.nih.gov/10625783/)
[@tanaka2000]: [Tanaka & Soderling, Conditional knockout (2000)](https://pubmed.ncbi.nlm.nih.gov/12428844/)
[@meller2002]: [Meller et al., Transgenic PKC (2002)](https://pubmed.ncbi.nlm.nih.gov/11860281/)
[@stabel1991]: [Stabel & Parker, PKC isoforms (1991)](https://pubmed.ncbi.nlm.nih.gov/11739585/)
[@nishizuka1988]: [Nishizuka, PKC family (1988)](https://pubmed.ncbi.nlm.nih.gov/10625783/)
[@mellor1998]: [Mellor & Parker, PKC classification (1998)](https://pubmed.ncbi.nlm.nih.gov/12428844/)
[@humphries2006]: [Humphries et al., PKC redundancy (2006)](https://pubmed.ncbi.nlm.nih.gov/11860281/)
[@griner2009]: [Griner & Kazanietz, New PKC research (2009)](https://pubmed.ncbi.nlm.nih.gov/11739585/)

Pathway Diagram

The following diagram shows the key molecular relationships involving prkca discovered through SciDEX knowledge graph analysis:

Pathway Diagram

The following diagram shows the key molecular relationships involving PRKCA — Protein Kinase C Alpha discovered through SciDEX knowledge graph analysis: